Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA
26:19
Common CMC Issues in Type II DMFs and How to Avoid Them
1:57:16
M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance
52:11
Overview: Clinical Pharmacology Considerations for Food Effect Studies
2:35:24
An In-Depth Look at the Final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs
2:47:58
FDA FY2025 Small Business Fair
44:31
Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018
7:46:16
188th Meeting of the Vaccines and Related Biological Products Advisory Committee Meeting
4:38:30